Fred Lublin, MD

Fred D. Lublin, MD
Saunders Family Professor of Neurology
Director, Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Mount Sinai School of Medicine
New York, New York

Fred D. Lublin, MD, is the Saunders Family Professor of Neurology at Mount Sinai School of Medicine and Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at that institution.

Dr. Lublin received his medical degree in 1972 from Jefferson Medical College, Philadelphia, PA.  He completed his internship in internal medicine at the Bronx Municipal Hospital, Albert Einstein Medical Center, and his residency at the New York Hospital, Cornell Medical Center.

Dr. Lublin has a special interest in immune functions and abnormalities affecting the nervous system. His involvement in both basic science and clinical research has resulted in numerous publications. He and his colleagues were among the first in the country to apply interferon beta-1b to the treatment of relapsing-remitting multiple sclerosis (MS), leading to its approval for that indication in 1993. He is currently involved with several clinical research protocols on promising agents for treating various aspects of MS. Dr. Lublin belongs to many professional societies and advisory boards. He was chairman of the National MS Society (NMSS-USA), Advisory Committee on Clinical Trials of New Drugs for MS, and the society’s Research Programs Advisory Committee.  He is currently a member of the NMSS National Board of Directors. He also chairs the New York City/Southern New York Chapter of the NMSS Clinical Advisory Committee. He is a member of the executive committee of the International Medical and Scientific Board of the Multiple Sclerosis International Federation. Dr. Lublin and his colleagues at the NMSS have redefined the clinical course definitions of MS using data from a survey of the international MS community. He has chaired a task force on the ethics of placebo-controlled trials in MS. Dr. Lublin is also a member of the international panel that periodically redefines the diagnostic criteria for MS. Dr. Lublin has served as a consultant to the National Institutes of Health and to many pharmaceutical/biotech companies in all phases of new drug development and preparation for presentation to the FDA and their advisory panels.  He is the Principal Investigator of the NIH-sponsored multicenter Combination Therapy Study in Multiple Sclerosis.